Splenosis is the result of spleen tissue breaking off the main organ and implanting at another site inside the body. This is called heterotopic autotransplantation of the spleen. It most commonly occurs as a result of traumatic splenic rupture or abdominal surgery. Depending on the location of the spleen, the new piece usually implants in another part of the abdominal cavity (including the pelvic cavity). Single case reports also describe splenosis in the thoracic cavity, in subcutaneous tissue, in the liver or in the cranial cavity. Splenosis must be distinguished from the presence of additional spleens, which are innate and are the result of differences in embryological development. Additionally, splenosis must be differentiated from malignant tumors which may look similar when imaged. History
Ectopic splenic tissue was first described in 1896 by Albrecht in Germany, whereas the term “splenosis” was first used by Buchbinder and Lipkoffin to describe their findings in 1939

Cause
A necessary requirement for splenosis is the rupture of the spleen, through a traumatic injury (such as a car wreck) or abdominal surgery, especially splenectomy. Splenosis in the abdominal category may occur in up to 65% of traumatic ruptures of the spleen. Splenosis in the thoracic cavity is rarer, because it requires the simultaneous rupture of the diaphragm. The implantation of spleen tissue under the skin may result from abdominal surgery or gunshot wounds. Splenosis of the brain or liver is hypothesized to be the result of tiny pieces of spleen tissue traveling through the bloodstream.
Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified to remove various proteins and other substances. FSH is important in the development of follicles (eggs) produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. It is also used with in vitro fertilization methods. The dosage is adjusted to each individuals response.The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma. It is not for use during pregnancy, as there is evidence for birth defects under follitropin treatment.Bravelle sold in the United States from March 2014 through October 2015 is subject to a recall and refund by its maker, Ferring Pharmaceuticals, because certain batches of the medicine had a lower strength than stated. References
External links
Bravelle, by Ferring Pharmaceuticals, Switzerland
Fostimon by Institut Biochemique SA, Switzerland